TM38837 是一种外周选择性大麻素受体1型 (CB1) 受体拮抗剂。TM38837 对大脑的渗透率有限，以最小化或防止 CNS 不良反应，并保留潜在的抗肥胖作用。TM38837 减少精神病副作用的倾向。
TM38837 is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. TM38837 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. TM38837 reduces propensity for psychiatric side effects[1][2].
[1]. Micale V, et al. The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows ReducedFear-Promoting Effects in Mice. Front Pharmacol. 2019 Mar 20;10:207. [2]. Klumpers LE, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):846-57.
动态评分
0.0